

News Releases

All Years

Search

Go

[Advanced Search](#)

NOV 14, 2025

Inhibrx Reports Third Quarter 2025 Financial Results

NOV 4, 2025

Inhibrx Announces Participation in Upcoming Scientific Conferences

OCT 23, 2025

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

OCT 22, 2025

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

AUG 13, 2025

Inhibrx Reports Second Quarter 2025 Financial Results

MAY 14, 2025

Inhibrx Reports First Quarter 2025 Financial Results

APR 1, 2025

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

MAR 17, 2025

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

JAN 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

JAN 13, 2025

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Show 10  per page

«	1	2	3	4	5	6	7	8	»
-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------



<https://inhibrxbiosciences.investorroom.com/news-releases?l=10&o=10>